Lymph node volume predicts survival in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy and surgery
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0300173 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Tzu-Hui Pao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Radiation Oncology, Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University,…. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Cheng Kung University Hospital.
Abstract (Originalsprache)
Large primary tumor volume has been identified as a poor prognostic factor of esophageal squamous cell carcinoma (ESCC) treated with definitive concurrent chemoradiotherapy (CCRT). However, when neoadjuvant CCRT and surgery are adopted, the prognostic impact of primary tumor and lymph node (LN) volume on clinical outcomes in ESCC remains to be elucidated. This study included 107 patients who received neoadjuvant CCRT and surgery for ESCC. The volume of the primary tumor and LN was measured using radiotherapy planning computed tomography scans, and was correlated with overall survival (OS), disease-free survival (DFS), and cancer failure pattern. The median OS was 24.2 months (IQR, 11.1–93.9) after a median follow-up of 18.4 months (IQR, 8.1–40.7). The patients with a baseline LN volume > 7.7 ml had a significantly worse median OS compared to those with smaller LN volume (18.8 vs. 46.9 months, p = 0.049), as did those with tumor regression grade (TRG) 3–5 after CCRT (13.9 vs. 86.7 months, p < 0.001). However, there was no association between OS and esophageal tumor volume (p = 0.363). Multivariate analysis indicated that large LN volume (HR 1.753, 95% CI 1.015–3.029, p = 0.044) and high TRG (HR 3.276, 95% CI 1.556–6.898, p = 0.002) were negative prognostic factors for OS. Furthermore, large LN volume was linked to increased locoregional failure (p = 0.033) and decreased DFS (p = 0.041). In conclusion, this study demonstrated that large LN volume is correlated with poor OS, DFS, and locoregional control in ESCC treated with neoadjuvant CCRT and esophagectomy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Radiation Oncology, Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Department of Medical Imaging, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
ORCID-Profile: Forn-Chia Lin
Förderung
- National Cheng Kung University Hospital
Zitieren
APA
Pao, T. H., Chen, Y. Y., Chang, W. L., Wu, S. Y., Lai, W. W., Tseng, Y. L., Chung, T. J., & Lin, F. C. (2024). Lymph node volume predicts survival in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy and surgery. PLOS ONE. https://doi.org/10.1371/journal.pone.0300173
Vancouver
Pao TH, Chen YY, Chang WL, Wu SY, Lai WW, Tseng YL, et al. Lymph node volume predicts survival in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy and surgery. PLOS ONE. 2024. doi:10.1371/journal.pone.0300173
BibTeX
@article{Pao2024,
author = {Pao, Tzu-Hui and Chen, Ying-Yuan and Chang, Wei-Lun and Wu, Shang-Yin and Lai, Wu-Wei and Tseng, Yau-Lin and Chung, Ta-Jung and Lin, Forn-Chia},
title = {Lymph node volume predicts survival in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy and surgery},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0300173}
}
EUVIMED